Abstract
Prezentarea cazului.

Se prezintă cazul unei paciente în vârstă de 56 ani, diagnosticată în 1992 cu LES cu manifestări cutanate (eritem în vespertilio), articulare (poliartrită), serozitice (pleuro-pericardită masivă) și imunologice (Ac anti-ADNdc pozitivi, C3 scăzut), ignorată terapeutic o perioadă îndelungată.
În 2010 acuză dispnee la eforturi medii și edeme gambiere, cu creșterea marcată a PAPs la ecocord. Este diagnosticată cu HTAP severă (confirmată prin cateterism cardiac drept) și se începe la Institutul Nasta tratament cu un blocant de receptor de endotelină (Bosentan) în combina ie cu un agonist de prostaciclină (Selexipag
Reasons for hospital admission
In April 2015 the patient was admitted to our clinic referred from the "Marius Nasta" National Institute of Pneumology for the reassessment of the SLE, complaining of important increase in volume of the abdomen and leg edemas with onset in the last months prior to the hospital admission.
History of the disease
The onset of the SLE was in 1992, at the age of 30 years, and in the same year she was diagnosed in our Clinic with SLE with cutaneous m a n i f e s t a t i o n s ( b u t t e r f l y -s h a p e d erythematous rash) and joint manifestations 
t o p p e d b y t h e p a t i e n t d u e t o t h e g a s t r o i n t e s t i n a l a d v e r s e r e a c t i o n s (vomiting).
Subsequently she received Methotrexate, but it was also discontinued after a year from the patient's own initiative. As the serositis Since April 2014 she started having ascites in high amount, accompanied by leg edemas, for which she was referred to our clinic.
Clinical examination
At the time of admission to our Clinic, the patient had no fever, she had skin changes specific to the SLE (butterfly-shaped erythematous rash), the abdomen was markedly increased in volume due to fluid overload, and she had central cyanosis. She was in atrial fibrillation and the respiratory system was well balanced.
Investigations
The laboratory tests showed decreased 
Some manifestations and immunological changes were identified as predictors of PAH in observational studies. In an analysis on a Chinese cohort, pleurisy was an independent predictive factor of PAH in lupus . The (2) antibodies specific to the antiphospholipid syndrome, especially anticardiolipin antibodies and lupus anticoagulant, were associated with a high risk of PAH. In our case both risk factors were present. PAH . The treatment should be promptly (3) initiated in order to increase survival. In our patient, the evolution on cortisone treatment in pulse therapy and Hydroxychloroquine was spectacular, with the disappearance of the massive ascites and the decrease with over 30% of the NT-proBNP, a prognostic marker in PAH . The introduction of ( 4 ) Cyclophosphamide was discussed, but due to the favorable evolution it was not considered necessary; additionally the risk of adverse reactions was high due to the age of the patient and the co-morbidities.
Conclusions
A case of SLE with multiple complications, with an acute episode of the disease with massive ascites and severe secondary pulmonary arterial hypertension at more than 20 years after the diagnosis, which required the increase of the immunosuppressive therapy.
